Suggestions
Gwen Cheni
Building in AI+Bio | ex-Khosla, IndieBio, Goldman, UCSF, Yale
Gwen Cheni is a prominent figure in the venture capital and startup ecosystem, currently working on a stealth startup project. Here's what we know about her:
Current Role
Gwen is the co-founder of a stealth startup that focuses on AI and biology.46 While the specific details of this venture are not publicly disclosed due to its stealth nature, it appears to be at the intersection of cutting-edge technologies.
Professional Background
Gwen has an extensive background in venture capital and investing:
- She was previously a Partner on the investment team at Khosla Ventures.46
- She served as a Partner at IndieBio NY, where she advised and invested in companies at various growth stages.5
- Earlier in her career, she was a Venture Partner at Fusion Fund, an early-stage venture fund in Palo Alto.1
- She has also been an Entrepreneur in Residence at Singularity University Ventures.1
Investment Experience
Gwen's investment experience is diverse:
- She spent 18 years as a public equities analyst and portfolio manager.1
- She started her career as an Analyst at Goldman Sachs and an Associate at JPMorgan.1
- She began angel investing in 2012.1
Education and Credentials
Gwen holds a CFA (Chartered Financial Analyst) designation.5 She received her education from Yale University.2
Additional Roles and Interests
- Gwen is known to be a frequent speaker and judge at startup pitch contests.1
- She has a particular interest in building companies with founders, appreciating entrepreneurs for their creativity and problem-solving abilities.1
Social Media Presence
Her LinkedIn username is indeed gweninvestor2, and she maintains a presence on Twitter as well.3
Gwen Cheni's diverse experience in finance, venture capital, and entrepreneurship, combined with her current work on a stealth startup, positions her as a notable figure in the tech and investment landscape.
Highlights
Takeaways from the insightful FDA Commissioner Robert Califf, at the Stanford Drug Discovery Symposium today:
- Decision-support algorithm is unlikely to be regulated by the FDA because there are too many of them, and a lack of reliable systems for continuously monitoring and full follow-up of the patients.
- FDA is the referee: do the benefits outweigh the risks. FDA is more concerned with safety and risks, not tasked with the bottom line.
- Biggest area of unmet need is in the post-market space. e.g. In Israel, CMS, FDA and medical records are one system, thus pricing will be adjusted in the future based on efficacy.
- FDA is making an effort to work across HHS, e.g. joint effort CDC+NIH for vaccines. Better communication via the FDA website, and at the point of care with primary care. Ensure technological wizardry accrue to better outcomes.
#SDDS2024 #drugdiscovery #fda #clinicaltrials #biotech #aiml #artificialintelligence
Good reasons for structural biology, by Patrick Cramer at the Max Planck Institute for Biophysical Chemistry/University of Gottingen
#structuralbiology #biotech #rna #proteinfolding #alphafold #mrna #crispr #crisprcas9 #cryoem #crystallography
